Puleva Biotech milestones
Puleva Biotech is the world leader in the sale of LC-Omega3 in terms of licensing its know-how, Omega 3 sales and the development of products that incorporate this fatty acid.
Following the acquisition of Exxentia, Puleva Biotech is now the European leader in biotechnology applied to the extraction of active principles from plants.
Puleva Biotech + Exxentia revenue
€, 000
| Spain | EU | US | RoW | |
| 2008 | 2,628 | 761 | 279 | 701 |
| 60% | 17% | 6% | 16% | |
| 2007 | 2,566 | 1.474 | 510 | 570 |
| 50% | 29% | 10% | 11% |
| Spain | EU | US | RoW | |
| 2008 | 4,307 | 3,512 | 809 | 805 |
| 46% | 37% | 9% | 9% | |
| 2007 | 4,942 | 3,415 | 764 | 570 |
| 51% | 35% | 8% | 6% |
Puleva Biotech today markets its products in 30 countries. It aims to continue expanding its geographic footprint by leveraging its powerful sales and marketing structure to bring products that combine all the scientific knowledge built up by the Group in recent years to final customers worldwide.
Puleva Biotech is a leading biotech player, with the capacity to develop bioactive ingredients that form the basis of the development of drugs, diet supplements and functional foods which in turn lead to healthier hearts and joints, facilitate weight control, cognitive development, ease aging, and strengthen the immunological system.
| Share capital | 13,847,885.28 |
|---|---|
| Number of shares outstanding | 57,699,522 |
| Share price (31/12/08) | €0,89 |
